Journal of HIV & Retro Virus
ISSN: 2471-9676

Open access Commentary

Drug Drug Interactions are Involoved in Antiretroviral Therapy

Virginia Woolf*

Department of HIV, University of Michigan, United Kingdom

DESCRIPTION

Antiretroviral pills have dramatically progressed the morbidity and mortality of human beings residing with HIV (PLWH). While contemporary antiretroviral therapy (ART) regimens are typically well-tolerated, dangers for aspect outcomes and toxicity continue to be as PLWH need to take life-lengthy medications. Antiretroviral pills effect autophagy, an intracellular proteolytic manner that gets rid of particles and overseas material, presents vitamins for metabolism, and plays great manage to hold mobileular homeostasis. Toxicity and unfavourable activities related to antiretrovirals can be due, in part, to their influences on autophagy.

Current HIV treatment regimens provide sustained virological suppression, restore the immune system at least partially, and have limited side effects. However, they do not allow the virus to be eradicated and have a lifelong obligation to people living with HIV (PHIV) through daily pill intake. Injectable drugs can lead to breakthrough changes in the management of PHIV, with reduced frequency of antiretroviral therapy (ART), widespread use of pre-exposure prophylaxis (PrEP), and drugs in the blood. Allowing level stabilization and approaching illness, the HIV pandemic ends.

Antiretroviral drugs are the lifeline of patients living with HIV. Side effects can impair compliance with antiretroviral therapy. The purpose of this study was to estimate the prevalence of side effects and their risk factors in HIV patients receiving antiretroviral therapy. As antiretroviral therapy (ART) becomes more affordable and accessible to potentially childbearing women around the world, children exposed to the human immunodeficiency virus (HIV) but not infected the numbers are increasing and almost all of them are also exposed to the perinatal period. Although ART has been successful in reducing mother-to-child transmission of HIV, the long-term effects of intrauterine exposure to ART on fetal and postnatal neurodevelopment remain unclear. Assessing the safety and efficacy of therapeutic agents for pregnant women may alter the historical limitations of including them in clinical trials and the pharmacokinetics of drug metabolism and fetal drug exposure. Difficult due to the dynamic physiological conditions inside.

CONCLUSION

The presence of hypertension in the human immunodeficiency virus (HIV) population poses a new threat to the health and well-being of people living with the disease, especially among those who have received antiretroviral therapy. The estimated prevalence of hypertension in HIV-infected patients is significantly higher than that observed in non-HIV-infected individuals. Approaching HIV-positive patients requires an assessment of individual cardiovascular risk and its consideration in designing individual goals. On the other hand, the numerous pharmacological interactions of antiretroviral drugs (ARVs) are important factors to consider. Serum levels of all types of antihypertensive drugs can be affected by the combination administration of protease inhibitors, non-nucleoside reverse transcriptase inhibitors, or other anti-retroviral drugs.

Drug interactions (DDI) have been a clinical challenge in HIV medicine for over 20 years. The new antiretroviral drug (ART) has significantly lower DDI than protease inhibitors and boost integrase inhibitors (INSTI). The reduced propensity for these new anti-retroviral drugs (eg, unboosted integrase inhibitors, Dravirin) to cause DDI is due to the aging of patients with multiple comorbidities taking multiple chronic drugs. It is largely offset by the cohort. In addition, new drugs can cause DDI and change the efficacy and toxicity of concomitant antiretroviral drugs, so the introduction of new drugs into clinical practice should be carefully monitored.

ACKNOWLEDGEMENT

None

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Received:	02-March-2022	**Manuscript No:**	IPJHRV-22- 13243
Editor assigned:	04- March-2022	**PreQC No:**	IPJHRV-22- 13243 (PQ)
Reviewed:	18-March-2022	**QC No:**	IPJHRV-22- 13243
Revised:	22-March-2022	**Manuscript No:**	IPJHRV-22- 13243 (R)
Published:	29-March-2022	**DOI:**	10.21767/2471-9676.8.2.08

Corresponding author Virginia Woolf, Department of HIV, University of Michigan, United Kingdom; E-mail: Virginia987@gmail.com

Citation Virginia W (2022). Drug Drug Interactions are Involoved in Antiretroviral Therapy J HIV Retrovirus.8:8.